PMID- 17432713
OWN - NLM
STAT- MEDLINE
DCOM- 20070502
LR  - 20220317
IS  - 0022-3085 (Print)
IS  - 0022-3085 (Linking)
VI  - 106
IP  - 4
DP  - 2007 Apr
TI  - Short-term and long-term safety of deep brain stimulation in the treatment of 
      movement disorders.
PG  - 621-5
AB  - OBJECT: The object of this study was to assess the long-term safety of deep brain 
      stimulation (DBS) in a large population of patients with a variety of movement 
      disorders. METHODS: All patients treated with DBS at the authors' center between 
      1995 and 2005 were assessed for intraoperative, perioperative, and long-term 
      adverse events (AEs). A total of 319 patients underwent DBS device implantation. 
      Of these 319, 182 suffered from medically refractory Parkinson disease; the other 
      patients had essential tremor (112 patients), dystonia (19 patients), and other 
      hyperkinetic movement disorders (six patients). Intraoperative AEs were rare and 
      included vasovagal response in eight patients (2.5%), syncope in four (1.2%), 
      severe cough in three (0.9%), transient ischemic attack in one (0.3%), arrhythmia 
      in one (0.3%), and confusion in one (0.3%). Perioperative AEs included headache 
      in 48 patients (15.0%), confusion in 16 (5.0%), and hallucinations in nine 
      (2.8%). Serious intraoperative/perioperative AEs included isolated seizure in 
      four patients (1.2%), intracerebral hemorrhage in two patients (0.6%), 
      intraventricular hemorrhage in two patients (0.6%), and a large subdural hematoma 
      in one patient (0.3%). Persistent long-term complications of DBS surgery included 
      dysarthria (4.0%), worsening gait (3.8%), cognitive dysfunction (4.0%), and 
      infection (4.4%). Revisions were completed in 25 patients (7.8%) for the 
      following reasons: loss of effect, lack of efficacy, infection, lead fracture, 
      and lead migration. Hardware-related complications included 12 lead fractures and 
      10 lead migrations. CONCLUSIONS: The authors conclude that in their 10-year 
      experience, DBS has proven to be safe for the treatment of medically refractory 
      movement disorders.
FAU - Kenney, Christopher
AU  - Kenney C
AD  - Parkinson's Disease Center and Movement Disorders Clinic, Department of 
      Neurology, Baylor College of Medicine, Houston, Texas 77030, USA. kenney@bcm.edu
FAU - Simpson, Richard
AU  - Simpson R
FAU - Hunter, Christine
AU  - Hunter C
FAU - Ondo, William
AU  - Ondo W
FAU - Almaguer, Michael
AU  - Almaguer M
FAU - Davidson, Anthony
AU  - Davidson A
FAU - Jankovic, Joseph
AU  - Jankovic J
LA  - eng
PT  - Journal Article
PL  - United States
TA  - J Neurosurg
JT  - Journal of neurosurgery
JID - 0253357
SB  - IM
MH  - Adolescent
MH  - Adult
MH  - Aged
MH  - Aged, 80 and over
MH  - Deep Brain Stimulation/*adverse effects
MH  - Female
MH  - Follow-Up Studies
MH  - Globus Pallidus
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Movement Disorders/*therapy
MH  - Retrospective Studies
MH  - Subthalamic Nucleus
MH  - Time Factors
MH  - Treatment Outcome
MH  - Ventral Thalamic Nuclei
EDAT- 2007/04/17 09:00
MHDA- 2007/05/03 09:00
CRDT- 2007/04/17 09:00
PHST- 2007/04/17 09:00 [pubmed]
PHST- 2007/05/03 09:00 [medline]
PHST- 2007/04/17 09:00 [entrez]
AID - 10.3171/jns.2007.106.4.621 [doi]
PST - ppublish
SO  - J Neurosurg. 2007 Apr;106(4):621-5. doi: 10.3171/jns.2007.106.4.621.